Pharming Group (NASDAQ:PHAR) Shares Gap Down – Time to Sell?

Shares of Pharming Group (NASDAQ:PHAR) gapped down before the market opened on Tuesday . The stock had previously closed at $7.75, but opened at $7.51. Pharming Group shares last traded at $7.50, with a volume of 1,444 shares traded.

Analyst Ratings Changes

A number of equities analysts have weighed in on PHAR shares. Oppenheimer cut their price target on shares of Pharming Group from $31.00 to $30.00 and set an “outperform” rating on the stock in a research note on Monday, October 28th. HC Wainwright reiterated a “buy” rating and issued a $37.00 target price on shares of Pharming Group in a report on Thursday, October 24th.

Pharming Group Price Performance

The stock’s 50-day moving average is $8.26 and its 200-day moving average is $8.31. The company has a current ratio of 3.53, a quick ratio of 2.76 and a debt-to-equity ratio of 0.41.

Institutional Investors Weigh In On Pharming Group

A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC boosted its stake in Pharming Group (NASDAQ:PHAR) by 75.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 41,110 shares of the company’s stock after purchasing an additional 17,675 shares during the period. Silverberg Bernstein Capital Management LLC owned approximately 0.06% of Pharming Group worth $339,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 0.03% of the company’s stock.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.